Handelsbanken Fonder AB Sells 2,400 Shares of DaVita Inc. (NYSE:DVA)

Handelsbanken Fonder AB decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 17.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 11,500 shares of the company’s stock after selling 2,400 shares during the period. Handelsbanken Fonder AB’s holdings in DaVita were worth $1,720,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in DVA. JPMorgan Chase & Co. grew its holdings in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after buying an additional 92,014 shares during the period. KBC Group NV grew its holdings in shares of DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after buying an additional 2,636 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of DaVita by 23.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after buying an additional 56,389 shares during the period. Nordea Investment Management AB grew its holdings in shares of DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after buying an additional 12,339 shares during the period. Finally, abrdn plc grew its holdings in shares of DaVita by 1.2% in the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after buying an additional 2,180 shares during the period. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

DVA has been the subject of several research analyst reports. Barclays boosted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $162.80.

DaVita Price Performance

DVA stock opened at $143.08 on Wednesday. The stock has a 50-day moving average price of $160.77 and a two-hundred day moving average price of $158.21. The stock has a market cap of $11.45 billion, a PE ratio of 13.32, a price-to-earnings-growth ratio of 1.07 and a beta of 0.93. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1 year low of $124.42 and a 1 year high of $179.60.

DaVita (NYSE:DVA) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.